Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

CG Oncology (CGON) Net Income towards Common Stockholders: 2023-2024

Historic Net Income towards Common Stockholders for CG Oncology (CGON) over the last 2 years, with Dec 2024 value amounting to -$88.0 million.

  • CG Oncology's Net Income towards Common Stockholders fell 114.20% to -$43.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$151.4 million, marking a year-over-year decrease of 92.29%. This contributed to the annual value of -$88.0 million for FY2024, which is 29.85% down from last year.
  • Latest data reveals that CG Oncology reported Net Income towards Common Stockholders of -$88.0 million as of FY2024, which was down 29.85% from -$67.8 million recorded in FY2023.
  • CG Oncology's Net Income towards Common Stockholders' 5-year high stood at -$67.8 million during FY2023, with a 5-year trough of -$88.0 million in FY2024.
  • Over the past 2 years, CG Oncology's median Net Income towards Common Stockholders value was -$77.9 million (recorded in 2023), while the average stood at -$77.9 million.
  • Data for CG Oncology's Net Income towards Common Stockholders shows a maximum YoY decreased of 29.85% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows CG Oncology's Net Income towards Common Stockholders stood at -$67.8 million in 2023, then decreased by 29.85% to -$88.0 million in 2024.